clinical trial · NCT07156539
A Phase 3 Study of HS-20094 in Patients With T2DM
Jiangsu Hansoh Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 546
Type 2 DiabetesHS-20094 InjectionDulaglutide Injection
brief summary
The study is being conducted to evaluate the efficacy and safety of HS-20094 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors compared to Dulaglutide QW for 44 weeks and 52 weeks.
started
Sep 30, 2025
primary completion
Mar 30, 2027
completion
May 30, 2027
last updated
Sep 5, 2025
official title
A Study of HS-20094 Versus Dulaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabete
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol